Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients

The Δ32-CCR5 deletion of the CCR5 receptor is protective toward coronary artery pathology and myocardial infarction. Maraviroc (MVC), a CCR5 antagonist, was recently introduced in the therapy of HIV infection; we evaluated whether this drug could modulate the atherosclerotic burden in aviremic PI-tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Piconi, Stefania, Pocaterra, Daria, Rainone, Veronica, Cossu, Maria, Masetti, Michela, Rizzardini, Giuliano, Clerici, Mario, Trabattoni, Daria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926207/
https://www.ncbi.nlm.nih.gov/pubmed/27352838
http://dx.doi.org/10.1038/srep28853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926207/
https://www.ncbi.nlm.nih.gov/pubmed/27352838
http://dx.doi.org/10.1038/srep28853

Ejemplares similares